ANCA announced the launch of its InsertsPRO special inserts grinding package software product in September. According to the Australia-based CNC grinding technology company, InsertsPRO can support ...

University of Connecticut provides funding as a member of The Conversation US. A “black box” warning on a health product sounds pretty scary – maybe even more so when it’s suddenly being taken off the ...

Leqvio (inclisiran) is a prescription drug used to help treat certain types of high cholesterol. Leqvio comes in a prefilled syringe for injection under the skin. Leqvio contains the active drug ...

Novartis announced positive results from V-DIFFERENCE, a phase IV study evaluating Leqvio (inclisiran) compared to placebo, both administered on top of individually optimized lipid-lowering therapy ...

12:54, Sun, Aug 31, 2025 Updated: 12:57, Sun, Aug 31, 2025 A twice-yearly jab that combats cholesterol could revolutionise heart care, according to its creator. The drug, Leqvio, also known as ...

A cholesterol-busting jab that is administered twice a year has the potential to transform heart care, according to its developer. It comes as new trial data suggests Leqvio, also known as inclisiran ...

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain 1 85% ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

A groundbreaking cholesterol-lowering injection, administered just twice annually, could revolutionise heart disease management, its developers have claimed. New trial data for Leqvio, also known as ...

A cholesterol-busting jab that is administered twice a year has the potential to transform heart care, according to its developer. It comes as new trial data suggests Leqvio, also known as inclisiran ...

Basel, August 30, 2025 – Novartis today announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio® (inclisiran) compared to placebo, both administered on top of individually ...